Name | 4-amino-5-fluoro-1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one |
---|---|
Synonyms |
Reverset
Dexelvucitabine DFC YZ-817 D-D4FC 2',3'-didehydro-2,3-dideoxy-5-fluorocytidine INCB-8721 DPC-817 |
Description | Dexelvucitabine (Reverset; d-d4FC), a Cytidine (HY-B0158) analog, is an orally active nucleoside reverse transcriptase inhibitor. Dexelvucitabine is a powerful drug against HIV-1-resistant viruses containing a thymidine analog and/or M184V mutation in the viral polymerase. Dexelvucitabine is a 2′-Deoxycytidine antiretroviral agent[1]. |
---|---|
Related Catalog | |
Target |
HIV-1 |
In Vivo | Dexelvucitabine (Reverset; d-d4FC; 33.3 mg/kg by i.v. or p.o.) has distribution and elimination half-lives (t1/2α and t1/2β, respectively) of 0.7 and 3.6 h in monkeys, respectively. The Cmax ranges from 21.1 to 47.5 μM[2]. Dexelvucitabine has a favorable pharmacokinetic profile with a long half-life (4.71 and 10.75 h after administration by the intravenous [i.v.] and oral [p.o.] routes, respectively) in woodchucks[2]. |
References |
Density | 1.66g/cm3 |
---|---|
Boiling Point | 394.9ºC at 760mmHg |
Molecular Formula | C9H10FN3O3 |
Molecular Weight | 227.19200 |
Flash Point | 192.6ºC |
Exact Mass | 227.07100 |
PSA | 90.37000 |
Vapour Pressure | 7.15E-08mmHg at 25°C |
Index of Refraction | 1.665 |
Storage condition | 2-8°C |
Precursor 5 | |
---|---|
DownStream 2 | |